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from the average HR for the overall SA population (74 bpm) could reduce SUS direct 
cost by over R$450 million. CONCLUSIONS: These results show that effective lower-
ing heart rate strategies may contribute to substantial savings of public funds in Brazil. 
Therefore, heart rate must be regarded as an important CV risk factor from an eco-
nomic point of view.
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OBJECTIVES: To assess the cost effectiveness of rivaroxaban against enoxaparin for 
the prevention of venous thromboembolism (VTE) in patients undergoing total hip 
replacement (THR) or total knee replacement (TKR) in a Colombian setting. 
METHODS: A cost-effectiveness model was developed to assess the cost effectiveness 
of rivaroxaban compared to enoxaparin in a Colombian setting over a 5-years time 
horizon. The model was divided into three modules: prophylaxis, post-prophylaxis, 
and long-term complications. The ﬁrst two modules constitute the acute phase and 
were represented in a decision tree while the long-term complications module was 
developed as a Markov process. Efﬁcacy and safety parameters used in the prophylaxis 
module were derived from the RECORD trials in the prevention of VTE following 
THR or TKR. Published epidemiological and clinical data were used to estimate the 
risk of VTE and other long term complications beyond the trial period. The analysis 
was performed from a health care payer’s perspective. Cost data was based on clinical 
guidelines, product labels, nationally and locally published sources, and expert 
opinion. VTE related utilities reported in literature were used in this analysis. One-way 
and probabilistic sensitivity analyses were performed in order to address uncertainty 
around the model inputs. RESULTS: Rivaroxaban dominated enoxaparin, yielding 
improved health outcomes (QALYs) and savings of COP 114,345 per patient in THR. 
Savings were driven mainly by reduced outpatient administration costs. Rivaroxaban 
also dominated enoxaparin with savings of 152,484 COP in TKR patients. Probabi-
listic sensitivity analyses showed dominance in 89% of cases in THR and in 99% in 
TKR. CONCLUSIONS: Rivaroxaban is a cost-effective alternative to enoxaparin for 
the prevention of VTE following THR or TKR in Colombia.
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COST-EFFECTIVENESS ANALYSIS OF DABIGATRAN ETEXILATE 
VERSUS ENOXAPARIN FOR THE PREVENTION OF VENOUS 
THROMBOEMBOLISM AFTER TOTAL HIP REPLACEMENT UNDER THE 
BRAZILIAN PUBLIC HEALTH CARE SYSTEM PERSPECTIVE
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OBJECTIVES: To develop a cost-effectiveness analysis of dabigatran etexilate versus 
enoxaparin for the prevention of venous thromboembolism after total hip replacement 
under the Brazilian public health care system perspective. METHODS: A decision tree 
analysis was developed for the ﬁrst 180 days, considering the occurrence of deep vein 
thrombosis (DVT), pulmonary embolism (PE) and all-cause mortality, followed by 
two Markov models, for post-thrombotic syndrome and thromboembolic pulmonary 
hypertension. Long term costs and outcomes associated with the prevention of venous 
thromboembolism in patients receiving dabigatran or enoxaparin were, therefore, 
projected. The cycle duration was 1 month and the corresponding transition probabili-
ties were obtained from the RE-NOVATE study. The outcomes were expressed as the 
incremental number of all thromboembolic events and deaths related to the surgical 
procedure and its acute and late complications. The analysis considered only direct 
medical costs. Unit costs for drugs and procedures were obtained from Kairos 
 Magazine (ex-factory price) and the National Database of Ambulatory Costs 
(SIA/DATASUS), respectively. Costs and outcomes were discounted at an annual 5% 
discount rate. A budget impact analysis was developed, considering the estimated 
number of total hip arthroplasties in the Brazilian public health care system in 2009. 
Main parameters were evaluated in a sensitivity analysis. RESULTS: After a literature 
review, the evidences showed similar effectiveness between both treatments. Total 
costs associated with dabigatran and enoxaparin were BRL667 (US$476) and 
BRL1,097 (US$784), respectively. The prophylaxis cost reduction was BRL430 
(US$307), in favor of dabigatran. In 2009, total annual costs estimated for dabigatran 
and enoxaparin were BRL7,425,815 (US$5,304,154) and BRL12,222,284 
(US$8,730,203), respectively, with a negative budget impact of BRL4,796,469. (2005 
purchasing power parity index 1USD  1.4BRL) CONCLUSIONS: Dabigatran 
showed to be as effective as enoxaparin and cost-saving for the prevention of venous 
thromboembolism after total hip replacement under the Brazilian public health care 
system perspective.
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OBJECTIVES: This study was designed to evaluate the cost-effectiveness of diagnostic 
assessment guided to B-Type Natriuretic Peptide compared with clinical judgment 
alone, in acute dyspnea, in the Uniﬁed Health System Scenario. METHODS: A Deci-
sion Analytic Model was developed to evaluate the cost-effectiveness of diagnostic 
assessment guided to B-Type Natriuretic Peptide compared with clinical judgment 
alone. We used effectiveness data described in a randomized, controlled clinical trial 
and data from ambulatory and hospital treatment costs coming from Brazilian studies 
on costs of Heart Failure. The effectiveness units were “hospital admissions avoided” 
and “echocardiography avoided”, at 60 days. The decision tree and statistical analyses 
were performed by the software TreeAge Pro Healthcare. RESULTS: The use of B-
Type Natriuretic Peptide in the diagnostic assessment of patients with acute dyspnea 
showed a reduction of echocardiography (-58.2%) and hospital admissions (-12.6%), 
when compared to the clinical judgment alone. The average cost per patient of B-Type 
Natriuretic Peptide group was BRL 652 (US$465) versus BRL 659 (US$470) of clinical 
group (2005 purchasing power parity index 1 USD  1.4 BRL*). CONCLUSIONS: 
We concluded that use of B-Type Natriuretic Peptide can be cost saving strategy, in 
the diagnostic assessment of patients presenting to acute care settings with dyspnea, 
in Uniﬁed Health System.
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COST-EFFECTIVENESS OF PHARMACOLOGIC HYPERTENSION 
THERAPY: ECONOMIC ANALYSIS OF ARBS IN COLOMBIA
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OBJECTIVES: Clinical evidence has demonstrated that considerable differences exist 
among various ARBs in terms of safety and efﬁcacy. These differences can lead to 
diverse economic outcomes depending on the chosen intervention. This analysis was 
aimed to assess the cost-effectiveness of ARBs available in the Colombian market. 
METHODS: We performed a cost-effectiveness ratio analysis of ARBs in Colombia. 
A systematic review was performed on available evidence. Head-to-head studies com-
paring Irbesartan with other ARBs were included and costs were evaluated based on 
a Colombian pricelist publication. Cost-effectiveness ratio was ﬁnally calculated with 
the efﬁcacy of interventions (systolic and diastolic mmHg reduction) in the analyzed 
trials. A sensitivity analysis was performed. RESULTS: Based on Mancia et al. 
[BloodPressMonit 2002;7: 135–42] and drug cost in the Colombian market, cost-
effectiveness for Irbesartan 150 mg was U$10.42 per mmHg reduced in systolic blood 
pressure (SBP) and US$18 for diastolic blood pressure (DBP) compared with US$18.53 
in DBP and US$28.72 for SBP with Valsartan (80 mg). According to Bobrie et al. 
[AmJHypertens 2005;18:1482–8] the cost effectiveness ratio for Irbesartan/Hydro-
chlorothiazide was US$8.97 (SBP) and US$12.28 (DBP) per mmHg reduced compared 
with US$12.72 (SBP) and US$18.22 (DBP) for Valsartan/Hydrochlorothiazide. The 
results based on Oparil et al. [JClinH 2001;3:283–318] were US$13.26 (SBP) U$17.81 
(DBP) for Irbesartan 150 mg compared with U$19.09 (SBP) US$28.27 (DBP) for 
Losartan 50 mg. Results from analysis performed with Kassler-Taub [AJH 
1998;11:445–53] were US$820 (SBP) and U$11.50 (DBP) for Irbesartan 300 mg 
compared with US$13.41 (SBP) and $17.41 (DBP) for Losartan 100 mg. Finally, based 
on the Negro et al. [JEndocrinolInvest. 2006;29:957–61] the results were $23.02 (SBP) 
and US$30.42 (DBP) compared with US$27.95 (SBP) US$32.67 (DBP) for Telmisartan 
80 mg. CONCLUSIONS: This analysis shows that ARBs have different economic 
outcomes regarding hypertension treatment. Irbesartan shows a good cost-effective-
ness ratio compared with other ARBs in the Colombian context.
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COST-EFFECTIVENESS ANALYSIS OF DABIGATRAN ETEXILATE 
VERSUS ENOXAPARIN FOR THE PREVENTION OF VENOUS 
THROMBOEMBOLISM AFTER TOTAL KNEE REPLACEMENT UNDER  
THE BRAZILIAN PUBLIC HEALTH CARE SYSTEM PERSPECTIVE
Fernandes RA, Quintella FF, Teich VD
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OBJECTIVES: To develop a cost-effectiveness analysis of dabigatran etexilate versus 
enoxaparin for the prevention of venous thromboembolism after total knee replace-
ment, under the Brazilian public health care system perspective. METHODS: A deci-
sion tree analysis was developed for the ﬁrst 180 days, considering the occurrence of 
deep vein thrombosis (DVT), pulmonary embolism (PE) and all-cause mortality, fol-
lowed by two Markov models, for post-thrombotic syndrome and thromboembolic 
pulmonary hypertension. Long term costs and outcomes associated with the preven-
tion of venous thromboembolism in patients receiving dabigatran or enoxaparin were, 
therefore, projected. The cycle duration was 1 month and the corresponding transition 
probabilities were obtained from the RE-MODEL study. The outcomes were expressed 
as the incremental number of all thromboembolic events and deaths related to the 
surgical procedure and its acute and late complications. The analysis considered only 
direct medical costs. Unit costs for drugs and procedures were obtained from Kairos 
Magazine (ex-factory price) and the National Database of Ambulatory Costs 
(SIA/DATASUS), respectively. Costs and outcomes were discounted at an annual 5% 
discount rate. A budget impact analysis was developed, considering the estimated 
number of total knee arthroplasties in the Brazilian public health care system in 2009. 
Main parameters were evaluated in a sensitivity analysis. RESULTS: After a literature 
review, the evidences showed similar effectiveness between both alternatives. Total 
costs associated with dabigatran and enoxaparin were BRL279 (US$199) and BRL451 
(US$322), respectively. The prophylaxis cost reduction was BRL172 (US$123), in 
favor of dabigatran. In 2009, total annual costs estimated for dabigatran and enoxa-
parin were BRL1,113,412 (US$795,294) and BRL1,800,886 (US$1,286,347), respec-
tively, with a negative budget impact of BRL687,474 (US$491,053). (2005 purchasing 
power parity index 1USD  1.4BRL) CONCLUSIONS: Dabigatran showed to be as 
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effective as enoxaparin and cost-saving for the prevention of venous thromboembo-
lism after total knee replacement under the Brazilian public health care system 
perspective.
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OBJECTIVES: To perform a cost-effectiveness analysis of thrombolysis with alteplase 
within 3 hours after acute ischemic stroke versus conservative treatment under the 
Brazilian public health care system perspective. METHODS: A Markov model was 
developed simulating acute stroke treatment with conservative treatment or alteplase. 
Three-monthly cycles were considered, during which, patients might transit between 
ﬁve post-stroke disability states, based on the modiﬁed Rankin Scale. The probability 
of presenting intracerebral hemorrhage after alteplase treatment and transition prob-
abilities in the ﬁrst year were obtained from NINDS trial. For subsequent years, 1-year 
cycles were considered, to account for patients’ mortality. The outcomes were 
expressed as life years gained (LYG). Both direct costs and indirect costs were con-
sidered in the analysis. Costs and outcomes were discounted at 5% per year. Results 
were segmented by gender and calculated for different time horizons, ranging from 1 
to 30 years. Unit costs for drugs were obtained from the Brazilian Health Prices 
Database, hospitalization and procedure costs were extracted from the National 
Database of Hospital Costs (SIH/DATASUS). RESULTS: In one year, incremental 
LYG were 0.0324 for both genders, with incremental costs of BRL608 for men and 
BRL363 for women. The incremental cost-effectiveness ratio in 1 year was BRL18,765/
LYG (US$13,404) for men and BRL11,204/LYG (US$8,003) for women. After the 
second year, alteplase became cost-saving. The shorter length of hospitalization and 
reductions in rehabilitation needs and productivity losses overweighed incremental 
drug costs. (2005 PPP 1USD  1.4BRL). CONCLUSIONS: Thrombolytic therapy with 
alteplase in the ﬁrst three hours after stroke changes the natural history of disease, 
reducing both direct and indirect costs. In the long term, there are large scale resource 
savings for the Brazilian public health care system.
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COST EFFECTIVENESS ANALYSIS OF ROSUVASTATIN 10 MG VS. 
ATORVASTATIN 20 MG FOR THE TREATMENT OF 
HYPERCHOLESTEROLEMIA
Anaya P, López RJ, Polanco AC
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OBJECTIVES: Make a comparison between Atorvastatin 20 mg and Rosuvastatin 
10 mg in the treatment of hypercholesterolemia in the Mexican public institutions. 
METHODS: We performed a cost-effectiveness analysis comparing Atorvastatin 
20 mg with Rosuvastatin 10 mg. The effectiveness outputs were percentage of Low 
Density Lipoprotein Cholesterol (LDL-C) reduction and percentage of patients that 
achieve ATPIII goals after one-year treatment. Effectiveness variables were based on 
the results of the STELLAR study and costs were obtained from a local wholesaler 
(NADRO) prices list. We used the National Health and Nutrition Survey (ENSANUT) 
of 2006 to gather general prevalence information. Results are reported in U.S. dollars 
with and exchange rate of 15 MXN per dollar. RESULTS: Annual treatment cost of 
Rosuvastatin 10 mg was $558.04 and Atorvastatin 20 mg was $1,169.24. We found 
an annual difference of $611.2 per patient. This means that if all the population with 
hypercholesterolemia reported by the ENSANUT 2006 were treated with Rosuvastatin 
instead of Atorvastatin a total of $10,613 million would be saved by the payer. The 
cost of one patient achieving the ATPIII goal with Rosuvastatin was $680.13 while 
with Atorvastatin the cost was $1,565.88. Cost of 1% reduction of LDL-C was $12.18 
for Rosuvastatin and $27.45 for Atorvastatin. CONCLUSIONS: Rosuvastatin 10 mg 
is more effective in both measurements (achieving ATPIII goals and reducing LDL-C) 
and is less costly than Atorvastatin 20 mg, therefore dominates over the compared 
treatment. The use of Rosuvastatin 10 mg instead of Atorvastatin 20 mg translates in 
huge saving to the public institutions in Mexico.
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COSTO-EFECTIVIDAD DE ETEXILATO DE DABIGATRAN EN LA 
PROFILAXIS DE LA ENFERMEDAD TROMBOEMBOLICA VENOSA (ETV) 
ASOCIADA CON CIRUGIA DE CADERA EN EL PACIENTE ADULTO EN 
EL INSTITUTO MEXICANO DEL SEGURO SOCIAL (IMSS)
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OBJECTIVOS: En México se estima que existen q100 mil casos nuevos detectados/año 
de trombosis venosa profunda (TVP) que originan 500,000 días/hospitalización y 
que la tromboembolia pulmonar (TEP) tiene una mortalidad intra-hospitalaria cercana 
al 47%. El objetivo de este trabajo fue identiﬁcar la alternativa más costo-efectiva 
para la proﬁlaxis de la ETV desde la perspectiva del IMSS. METODOLOGÍAS: 
Evaluación económica completa. Se construyó un árbol de decisiones comparando los 
resultados en salud (estimados mediante meta-análisis) de tres alternativas anticoagu-
lantes actualmente disponibles en el IMSS (heparina más warfarina, enoxaparina y 
fondaparinux) y los costos de la atención en el contexto de esa institución, versus los 
resultados y costos alcanzados por el uso del innovador dabigatrán. RESULTADOS: 
El esquema proﬁláctico basado en heparina no fraccionada más warfarina fue tomado 
como comparador común por ser el de menor precio y uno de los más empleados. 
Dabigatrán resultó ser la alternativa dominante en la proﬁlaxis de TVP con una ICER 
de -$62.64 (IC95% $61.71–$63.57) por caso evitado. Lo mismo sucedió en el caso 
de TEP donde la ICER fue de -$1,002.28 (IC 95% $987.39–$1017.17) por 
caso evitado. Un análisis de sensibilidad multivariado conﬁrmó estos resultados. 
CONCLUSIONES: Debido a que dabigatrán es un medicamento oral, de dosis ﬁja y 
de efecto predecible, facilita un mayor apego al esquema proﬁláctico en comparación 
con el esquema comparador y con ello disminuye el riesgo de TVP o de TEP. Dabig-
atrán es la opción más eﬁciente para prevenir estos eventos en el contexto del IMSS.
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REVISÃO SISTEMÁTICA DE ESTUDOS DE CUSTO-EFETIVIDADE DA 
ROSUVASTATINA VS. ATORVASTATINA
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OBJETIVOS: Este estudo visa avaliar os estudos de custo–efetividade da Rosuvasta-
tina versus a Atorvastatina no tratamento da hipercolesterolemia e avaliar a necessi-
dade de incorporá-la no Brasil, pela listagem de Medicamentos Especiais para 
dislipidemias do Sistema Único de Saúde (SUS). MÉTODOS: Foi realizada uma busca 
nas bases de dados PubMed, Medline, Google Acadêmico, Bireme, Biblioteca do 
Centro Cochrane do Brasil, The Cochrane Library Clinical Evidence e Biblioteca do 
Conhecimento, de todos os estudos de custo–efetividade e Revisões Sistemáticas que 
avaliam a Rosuvastatina versus a Atorvastatina. Foram analisadas as populações 
envolvidas, a perspectiva do estudo, intervalo temporal, dados do estudo, medidas de 
efetividade, custos avaliados, modelagem econômico, taxas de desconto, análise de 
sensibilidade, limitações, conﬂitos de interesse, resultados principais. RESULTADOS: 
A Rosuvastatina, em diferentes dosagens, demonstrou em todos os estudos analisados 
ser mais custo–efetiva entre todas as estatinas comparadas, inclusive quando analisada 
com a Atorvastatina em relação à segurança, eﬁcácia e custo–efetividade. Em pacientes 
de alto-risco com hipercolesterolemia, a Rosuvastatina foi o medicamento que reduziu 
mais signiﬁcativamente os níveis de LDL e os custos de tratamento foram menores, 
diminuiu a quantidade de pacientes que realizaram novas consultas médicas necessi-
tando aumentar a dose do medicamento, bem como o número de exames laboratoriais. 
CONCLUSÕES: A rosuvastatina tem poucos estudos que a avaliem frente a outras 
estatinas. É necessário que estudos no Brasil sejam realizados, sem conﬂitos de inter-
esse, para avaliar mais profundamente a rosuvastatina. A rosuvastatina é efetiva, tem 
preços de venda mais baixos que a Atorvastatina podendo ser custo–efetivo incorporá-
la na Lista dos Medicamentos Especiais do SUS, para pacientes com hipercolesterol-
emia e risco alto para doenças cardiovasculares. Para pacientes com baixo risco e que 
necessitar menor redução de LDL-C poderão ser utilizadas estatinas que tenham 
menor custo e menor efetividade.
CARDIOVASCULAR DISORDERS – Patient-Reported Outcomes Studies
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METABOLIC SYNDROME PATIENT COMPLIANCE WITH DRUG AND 
NON-DRUG TREATMENT
Lopes N, Zanini AC
University of Sao Paulo, Sao Paulo, Brazil
OBJECTIVES: To evaluate compliance with drug treatment in patients with metabolic 
syndrome as well as weight loss and physical activity practicing during a 12-month 
follow-up. METHODS: This was a longitudinal study, with a 12-month follow-up, 
involving 45 patients with metabolic syndrome according to IDF criteria, who were 
being treated in a Health-Medical School Center under the Brazilian Healthcare 
System. Patients were evaluated every three months. The Measure Treatment Adher-
ence, a variation of the Morisky-Green Test, in a 1 to 6 scale, was used to assess 
patient behavior patterns associated with the use of medicines. Parameters to evaluate 
compliance with non-drug treatment were: to achieve a 10% weight reduction in total 
body weight and to perform a minimum of 30 minutes of physical activity at least 
three times a week. RESULTS: Average levels of compliance in each measurement 
were: 5.49 o 0.44 (at inclusion); 5.68 o 0.57 (3-month follow-up); 5.87 o 0.28 (6-
month follow-up); 5.79 o 0.44 (9-month follow-up); 5.72 o 0.46 (12-month follow-
up). At the end of 12-month period, 4 patient achieved weight reduction goal. Average 
% weight variations in relation to the established goal were: k10.2% o 2.9 (3-month 
follow-up); k10.0% o 6.5 (6-month follow-up); k10.1% o 7.2 (9-month follow-up); 
k10.5% o 7.5 (12-month follow-up). Patients who practiced no physical activity were: 
62% (at inclusion); 60% (3-month follow-up); 64% (6-month follow-up); 69% (9-
month follow-up); 69% (12-month follow-up). The majority of patients who practiced 
physical activities spent more than 30 minutes per exercise session. CONCLUSIONS: 
Patients involved in this study exhibited a high level of compliance with drug treat-
ment. More research is needed to conﬁrm if this result is characteristic of patients 
treated in a Health-Medical School Center. Although regular practice of physical 
activity and weight loss are associated with signiﬁcant clinical improvements, both 
these issues need to be better addressed.
